Related Experiment Videos
[Management of malignant pleural effusions].
1HELIOS Klinikum Emil von Behring, Lungenklinik Heckeshorn, Zentrum für Pneumologie und Thoraxchirurgie, Berlin. loddheck@zedat.fu-berlin.de
Pneumologie (Stuttgart, Germany)
|February 23, 2005
Summary
Malignant pleural effusions, often caused by lung cancer, present a common challenge in cancer patients. This overview details diagnosis, treatment like pleurodesis, and prognosis for these effusions.
Area of Science:
- Oncology
- Pulmonology
- Clinical Medicine
Context:
- Malignant pleural effusions are a common complication in patients with advanced cancer.
- Lung carcinoma, breast carcinoma, and malignant lymphoma are leading causes.
- The incidence of malignant mesothelioma is rising globally.
Purpose:
- To provide a comprehensive overview of the diagnostic and therapeutic approaches to malignant pleural effusions.
- To discuss differential diagnoses, including paramalignant effusions.
- To highlight current and future research directions for improved patient outcomes.
Summary:
- This review covers the epidemiology, diagnosis, and treatment of malignant pleural effusions based on the ERS/ATS Statement 2001.
- Key therapeutic strategies include pleurodesis, particularly thoracoscopic talc poudrage.
- Emphasis is placed on effusions associated with lung and breast carcinomas and lymphomas, detailing their specific management and prognosis.
Impact:
- Provides clinicians with updated information for managing malignant pleural effusions.
- Identifies areas for future research to enhance treatment efficacy and patient prognosis.
- Contributes to the understanding of a significant clinical problem in oncology and pulmonology.